

INTERVIEW

DR. NADYA LISOVODER

CEO OF GALILEE CLINICAL BIO RESEARCH

GROUND-BREAKING REMEDY BEATS COVID-19 SYMPTOMS DURING CLINICAL TRIALS

"COVID-19 ITSELF IS NOT PARTICULARLY DANGEROUS, but a patient's condition can worsen dramatically. This happens when there is an influx of cytokines, which are bioactive, inflammatory ingredients."

ArtemiC™ is a revolutionary food supplement that brings together the powerful anti-viral properties of four natural ingredients. To bring the fight directly to the cells and ensure the body can properly utilize every drop of the formulation, it uses patented MyCell™ technology to boost bioavailability. Dr. Nadya Lisovoder is the CEO of Galilee Clinical Bio Research, the clinical research organization responsible for managing the clinical development of ArtemiC, including: in-vitro clinical trials that proved the safety and non-toxicity of the formulation and Phase II clinical study of 50 patients with moderate COVID-19 symptoms. Lisovoder reflects on these studies, which demonstrated the ability of ArtemiC to combat cytokine storms and prevent the deterioration of symptoms in COVID-19 patients.

Q. What makes COVID-19 so dangerous?

A. "COVID-19 itself is not particularly dangerous, but a patient's condition can worsen dramatically. This happens when there is an influx of cytokines, which are bioactive inflammatory ingredients.

"Maybe the best parallel for a cytokine storm is cancer in the body: our cells renew themselves all the time and, usually, this process is totally controlled by our body. But if the new cells are a tumor, something is broken and there is an uncontrolled process of new cells being produced. It's the same thing with a cytokine storm.

"Normally, if we have inflammation, the body will produce cytokines to protect itself and to create the anti-inflammatory effect on the tissues. But when this process becomes uncontrolled, it's called the cytokine storm and this very dangerous condition has actually been the number one reason for mortality during the COVID-19 pandemic.

"Because of this, we see intubation and mechanical ventilation even in young patients who don't have a complicated medical history – even those patients can need medical interventions or die."

Q. What impact can ArtemiC have on a cytokine storm?

A. "ArtemiC was able to reduce the inflammation of cell tissue and prevent the incubated production of the cytokines that cause that uncontrolled inflammation. In the pre-clinical in-vitro trials, we took tissue that had been induced to produce cytokines and added a controlled dose of ArtemiC anti-inflammatory agent. What we found is that ArtemiC is capable of actually stopping the production of new cytokines."

**"ARTEMIC IS CAPABLE
OF ACTUALLY STOPPING
THE PRODUCTION OF NEW
CYTOKINES."**

Q. Who was involved in the Phase II clinical trial?

A. “We had 50 COVID-19 patients who were all hospitalized in two hospitals in Israel and one hospital in Mumbai. We took patients who were all in a moderate condition, which means they had a temperature and a potentially complicated medical history, like diabetes or metabolic syndrome or obesity – the things that we’ve heard over the last year are the risk factors for COVID-19. Those patients were hospitalized so, according to international guidelines they could not be classified as asymptomatic or mild.”

Q. How did the clinical trial work?

A. “We took 50 patients and divided them into two groups: placebo and treatment. After two weeks of treatment, we compared the clinical signs, laboratory tests and all the recommended scores for the evaluation of COVID-19 patients.

“We organized the groups to be two-to-one, which means that for every two patients who got the treatment, one got the placebo. We had 33 patients who got ArtemiC and only 17 who got the placebo.

“We compared using what’s called the NEWS tool score, which was recommended by the FDA as a main score to measure the improvement in the condition of COVID-19 patients. In this case, it’s temperature, COVID-related pain, oxygen saturation, pulse – the things that we know are related to COVID-19.

“We also asked questions like percentage of ICU admission, use of mechanical ventilation – all kinds of worsening in a patient’s condition.”

Q. Did ArtemiC prevent symptoms from worsening?

A. “What we saw in the pre-clinical trials with cytokines, we saw again in the patients. Patients who got ArtemiC completed the two week trial with a totally normal clinical condition – a normal NEWS score. We had no patients that were admitted to the ICU in the treatment group, there was no mechanical ventilation, no oxygen supply was needed.

“In the placebo group, after two weeks the NEWS score was totally abnormal and the difference between the two groups was statistically significant. That means we know it should work in bigger groups.

“Zero patients out of 33 in the treatment group required mechanical ventilation, ICU, additional oxygen. In the placebo group, 21% of patients need additional oxygen supply or mechanical ventilation. We had two patients that were transferred to the ICU and unfortunately one patient who died one day after the study was completed.

“All those differences between the two groups are very

**“ZERO PATIENTS
OUT OF 33 IN THE
TREATMENT GROUP
REQUIRED MECHANICAL
VENTILATION”**

**“WE HAD PATIENTS WITH
CHRONIC KIDNEY DISEASE,
RENAL FAILURE, LIVER
FAILURE, SO FROM THE POINT
OF VIEW OF POTENTIAL RISK,
WE HAD A VERY DIVERSE
POPULATION IN BOTH
GROUPS.”**

interesting because patients in both groups have a very complicated medical history and more chance to be severe patients. We had patients with chronic kidney disease, renal failure, liver failure, so from the point of view of potential risk, we had a very diverse population in both groups. Despite this fact, it was a very clear improvement in the treatment group versus continuation of the disease on day 15 in the placebo group.”

Q. What comes next for ArtemiC?

A. “Development is completed and it will be on the market as a food supplement. The clinical studies have been very consistent and we know that it works.”

Q. What are the potential benefits of ArtemiC as a supplement?

A. “What we know is that COVID-19 patients who are mild or moderate can take it and it should prevent the potential worsening of the disease. The idea of ArtemiC is to stop potential systemic inflammation and it’s important to say that ArtemiC will not only be useful for COVID-19. There are a lot of medical conditions that are related to the cytokine storm, like the flu, pneumonia, Crohn’s disease, rheumatoid arthritis. We believe there are numerous conditions where the centralized anti-inflammatory and immuno-modulative effect of ArtemiC can be very useful.”

Study Results

The study revealed that ArtemiC could have numerous advantages in the treatment of COVID-19, which include:

- A full safety and efficacy profile with no participants showing drug-averse reactions
- The ability to prevent symptoms from deteriorating
- Recover faster and maintain normal blood oxygen levels.
- Improvement of symptoms and pain
- The versatility to be utilized at home, as well as in hospitals

*Distributed in the US by AMC Pharma USA, LLC
201 East Kennedy Blvd, Ste 1611 Tampa, FL 33602
Info@amcpharma-usa.com*